Contact us EN FR

Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders .

Our mission is to radically improve the health of patients suffering from incurable life threatening conditions. We do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

Lysogene COVID-19 update

 

The safety of our MPS IIIA trial participants is our top priority. At Lysogene we are actively and continuously working with our clinical trial sites, regulatory authorities and ethics committees to assess potential impacts and reduce families’ potential exposure to COVID-19, whilst continuing to provide medically necessary study care. If you have any concern or question, please contact your study doctor.

 

In the clinic

MPS IIIA

Lysogene is currently recruiting for its global phase II/III clinical trial of LYS-SAF302, a gene therapy for the treatment of MPS IIIA. ... Read More


GM1 Gangliosidosis

Lysogene develops IND-supporting preclinical studies and plans its phase I/II clinical trial of gene therapy in GM1 gangliosidosis ... Read More

Latest tweet

Get in touch

Follow us

Join our mailing list

arrow-left arrow-right calendar contact download facebook linkedin location play reset rss twitter youtube